Trufin PLC (TRFNF) (H1 2026) Earnings Call Highlights: First Half EBITDA Profitability and a ...

Negative Points

• TruFin PLC ( TRFNF ) faces uncertainty regarding future capital allocation, with no specific timeframe or clear plan for the GBP25 million cash pile.

• The company's cost base may need to increase as Satago grows, potentially impacting future profitability despite current cost control.

• Oxygen's growth is subject to external factors like the Procurement Act, which caused tender volume volatility and may continue to affect predictability.

• Satago's exceptional revenue growth is not expected to continue indefinitely, and the timing of its pipeline conversion remains uncertain.

• TruFin PLC ( TRFNF ) may face challenges in maintaining high operating leverage in Oxygen, as future investments could reduce EBITDA flow-through.

Q & A Highlights

Q: What's next for TruFin, and what are the plans for the large cash pile? Why should investors stay shareholders? A: CEO James van den Bergh said the company will look to allocate capital as efficiently as possible, with options including buying another platform business, bolt-on acquisitions for Oxygen, or returning money to shareholders via dividends or tender offers. He noted that half the market cap is in cash and TruFin owns two profitable businesses, adding that he has personally bought more shares because he believes the businesses are undervalued.

Q: As Satago transitions toward a higher-margin subscription model, what is the long-term margin profile and how much visibility is there on the LAS pipeline? A: CFO James Hussey said higher-margin subscription revenue should flow through significantly to the bottom line with only a small cost increase, though some team investment will eventually be needed as revenues grow. He noted a significant pipeline exists with confidence in some conversions, but timing remains difficult to predict.

Q: How much further operating leverage is there in Oxygen as revenue grows, and where will the sustainable EBITDA margin settle? A: CFO James Hussey said Oxygen has consistently delivered strong operating leverage, with revenue increases flowing almost entirely through to EBITDA. He expects this to continue for the foreseeable future, though occasional investment periods may interrupt the full flow-through in a given half or full year.

Q: Why did Satago's subscriber growth accelerate from January, and what is the total addressable market internationally? A: CEO James van den Bergh attributed the acceleration to a focused push by both Sage and Satago, describing their relationship as symbiotic. He said growth came without heavy marketing spend, and while the TAM is large given Sage's global scale, the exceptional growth rate cannot continue indefinitely. International expansion is under discussion.

Q: What were the key financial results for the first half of 2026 from continuing operations? A: CFO James Hussey reported total revenue of GBP5.9 million versus GBP5.3 million a year earlier. Satago contributed GBP1 million, up 41% (effectively doubling on a like-for-like basis after excluding prior interest income), while Oxygen grew 11% to just under GBP5 million. A GBP0.6 million revenue improvement drove a GBP0.7 million EBITDA improvement and over GBP1 million improvement in adjusted PBT.

Q: What is the status of Satago's path to profitability? A: CFO James Hussey said Satago achieved EBITDA profitability in June and was EBITDA profitable for the first half, and the company now forecasts full-year EBITDA profitability for Satago. CEO James van den Bergh reiterated that this was ahead of schedule and congratulated Sinead and her team.

Q: How has the Procurement Act affected Oxygen's tender volumes, and where do things stand now? A: CEO James van den Bergh explained that the February 2025 Procurement Act pulled forward purchases into January and February 2025, creating a subsequent vacuum and subdued tender volumes. Volumes have now normalized as of around June 2026, and the second half faces an easier comparative period.

Q: How predictable is Oxygen's revenue base? A: CEO James van den Bergh said over 90% of Oxygen's future revenue over the next four years is already baked in from existing clients, thanks to average five-year contracts in the early payment business. He described this as giving the business incredible visibility and predictability.

Q: How is Oxygen demonstrating its distribution capability? A: CEO James van den Bergh said more than 65% of Oxygen's early payment clients now buy two or more products, up from 53% in the prior-year first half. He highlighted distribution as a key competitive advantage, especially in an AI-driven world, and noted first-half EBITDA of GBP2.1 million nearly matched full-year 2024 EBITDA of GBP2.3 million.

Q: What did TruFin do with the proceeds from the PlayStack sale? A: CEO James van den Bergh said PlayStack was sold in June 2026 for GBP125 million, and proceeds were returned to shareholders via a buyback of 40.6 million shares at GBP1.40 and GBP22.5 million in dividends (43p per share). Over 18 months, TruFin bought back 52.6 million shares, or 49.6% of the company, leaving 53.9 million shares outstanding.

Q: What is the current trading performance in the second half of 2026? A: CEO James van den Bergh reported unaudited revenues in excess of GBP2.1 million for July and August, representing 28% year-over-year growth, an acceleration from 11% growth in the first half. He called it a pleasing start to the second half while cautioning it may not continue at that pace.

Q: What is TruFin's cash position and capital allocation philosophy? A: CEO James van den Bergh said TruFin holds approximately GBP25 million in cash, equating to 46.4p per share, about half the current market cap. He emphasized the company will allocate capital to generate the highest return with the lowest risk, and has proven it will not hoard cash, returning it to shareholders if that is the right decision.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .